Published in final edited form as:

Parasitology. 2019 April ; 146(5): 604–616. doi:10.1017/S0031182018001853.

Substrate Specificity of the Neutral Sphingomyelinase from *Trypanosoma brucei*

Emily A. Dickie¹, Simon A. Young, and Terry K. Smith

Biomedical Sciences Research Complex, Schools of Biology and Chemistry, University of St Andrews, Fife, KY16 9ST, UK

Abstract

The kinetoplastid parasite *Trypanosoma brucei* causes African trypanosomiasis in both humans and animals. Infections place a significant health and economic burden on developing nations in sub-Saharan Africa, but few effective anti-parasitic treatments are currently available. Hence, there is an urgent need to identify new leads for drug development. The *T. brucei* neutral sphingomyelinase (TbnSMase) was previously established as essential to parasite survival, consequently being identified as a potential drug target. This enzyme may catalyse the single route to sphingolipid catabolism outside the *T. brucei* lysosome. To obtain new insight into parasite sphingolipid catabolism, the substrate specificity of TbnSMase was investigated using electrospray ionization tandem mass spectrometry (ESI-MS/MS). Recombinant TbnSMase was shown to degrade sphingomyelin, inositol-phosphoceramide and ethanolamine-phosphoceramide sphingolipid substrates, consistent with the sphingolipid complement of the parasites. TbnSMase also catabolised ceramide-1-phosphate, but was inactive towards sphingosine-1-phosphate. The broad-range specificity of this enzyme towards sphingolipid species is a unique feature of TbnSMase. Additionally, ESI-MS/MS analysis revealed previously uncharacterised activity towards *lyso*-phosphatidylcholine, despite the enzyme's inability to degrade phosphatidylcholine. Collectively, these data underline the enzyme's importance in choline homeostasis and the turnover of sphingolipids in *T. brucei*.

Keywords

lipid catabolism; sphingolipid; choline; lipid extraction; mass spectrometry; enzyme; activity assay

Introduction

The kinetoplastid parasite *Trypanosoma brucei* causes African trypanosomiasis in both humans and animals. Human African trypanosomiasis (HAT) is considered fatal if left

Correspondence should be addressed to Terry K. Smith. Address: Biomedical Sciences Research Complex, Schools of Biology and Chemistry, University of St Andrews, Fife, KY16 9ST, UK. Telephone: +44(0)1334 463412. tks1@st-andrews.ac.uk.

¹Current address: Wellcome Trust Centre for Molecular Parasitology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8TA, UK

Conflicts of Interest

None

Ethical Standards

Not applicable

untreated, and poses a serious health risk to an estimated 65 million people in Sub-Saharan Africa (World Health Organization, 2017a). Recent efforts have led to a dramatic decrease in reported disease cases, with 2804 cases reported in 2015, although the World Health Organization estimates the actual number of cases to be 10-fold greater (World Health Organization, 2017a; b). Research has also produced promising new drug candidates, however, the risk of parasite resistance and consequent HAT re-emergence still threaten the progress made in combatting the disease. Animal trypanosomiasis remains a significant burden, with billions of US dollars lost through livestock infections each year and few treatment candidates on the horizon (Shaw *et al.*, 2014). Thus, there is an urgent need to identify leads for drug development.

T. brucei sphingolipid biosynthesis has long been identified as a potential drug target. Most eukaryotes are capable of synthesising their own sphingolipids via the *de novo* biosynthesis pathway (Fig. 1A), which is highly conserved amongst eukaryotic organisms (Kolter and Sandhoff, 1999). Although homologues of most of the enzymes involved in this biosynthetic pathway have been (putatively) identified in *T. brucei*, many still require biochemical characterisation (Smith and Bütikofer, 2010). The first reaction in the pathway, condensation of serine and palmitoyl-CoA, is catalysed by the enzyme serine-palmitoyltransferase (SPT) (Tidhar and Futerman, 2013). A homologue of this enzyme has been identified in *T. brucei*, which was shown to be essential for cell cycle progression and parasite survival (Fridberg *et al.*, 2008). Inhibiting the initial SPT-catalysed reaction of the *T. brucei de novo* biosynthesis pathway disrupted procyclic cytokinesis and kinetoplast segregation, validating the pathway as a drug target (Fridberg *et al.*, 2008; Smith and Bütikofer, 2010). Although SPT is known to be essential in other parasites, such as *Plasmodium falciparum* (Gerold and Schwarz, 2001), these findings contrast with research involving the related kinetoplastid parasite *Leishmania major* (Denny *et al.*, 2004; Zhang *et al.*, 2007). Unusually, *T. brucei* has four tandemly linked genes, each encoding different sphingolipid synthases (TbSLSs1-4) (Sevova *et al.*, 2010). This family of sphingolipid synthases is orthologous to the *S. cerevisiae AUR1*-encoded inositol-phosphoceramide (IPC) synthase (Mina *et al.*, 2009), and equivalent enzymes are found in both *Leishmania major* (Denny *et al.*, 2006) and *Trypanosoma cruzi* (De Lederkremer *et al.*, 2011). RNA interference (RNAi) against the *TbSLS1-4* gene locus in bloodstream trypanosomes impeded growth, ultimately leading to parasite death (Sutterwala *et al.*, 2008). This finding identified the TbSLSs as potential drug targets. The individual functional specificities of the four synthases were determined by employing a cell-free synthesis system (Sevova *et al.*, 2010). TbSLSs 1 and 2 synthesise IPC and ethanolamine-phosphoceramide (EPC) respectively (Sevova *et al.*, 2010). TbSLSs 3 and 4 are bi-functional, producing both SM and EPC (Sevova *et al.*, 2010). Research has indicated TbSLS substrate specificity is dictated by natural variations in a small number of active site residues, thought to be involved in acid-base catalysis (Goren *et al.*, 2011). Establishing the functions of the TbSLSs has clarified how the parasite is capable of altering its sphingolipid complement during its life cycle (Mina *et al.*, 2009; Sevova *et al.*, 2010), an observation further confirmed by recent sphingolipidomic analysis (Guan and Mäser, 2017). Currently, trypanosomatids are the only organisms known to synthesise sphingolipid species with choline, ethanolamine and inositol headgroups (Serricchio and Bütikofer, 2011; Guan and Mäser, 2017).

In comparison to the knowledge of *T. brucei* sphingolipid biosynthesis that has already been acquired, little is known of the processes involved in the parasites' sphingolipid catabolism. The catabolism of sphingolipids in eukaryotes takes place via the degradation pathway (Fig. 1B), predominantly in lysosomes and late endosomes, but also in other cellular locations (Kolter and Sandhoff, 1999; Jenkins *et al.*, 2009). A number of different enzymes are involved in the degradative process (ceramidases, lyases, phospholipase D), but one major group of proteins responsible for sphingolipid turnover in mammalian cells is the sphingomyelinase (SMase) enzyme family (Kolter and Sandhoff, 1999). As indicated by their name, the primary substrate of these enzymes in mammals is SM, which is hydrolysed to yield ceramide and choline-phosphate (ChoP) (Jenkins *et al.*, 2011). *T. brucei* has a single neutral SMase (TbnSMase) (Q57U95), a membrane protein with two identified transmembrane domains at its C-terminus (Young and Smith, 2010). TbnSMase has been localised to the ER in bloodstream form parasites, and genetically confirmed as a potential drug target (Young and Smith, 2010). The activity of this protein is thought to be essential due to its intrinsic roles in vital biochemical processes, including choline and ceramide homeostasis, and endocytosis. This is particularly relevant to the coupling of endocytic and exocytic mechanisms with post-Golgi sorting of GPI-anchored variant surface glycoprotein (VSG), which is needed to maintain VSG surface density (Young and Smith, 2010). VSG molecules form the protective coat that permits *T. brucei* parasites to evade the host immune system (Mugnier *et al.*, 2016). The importance of TbnSMase corroborates findings relating to the single leishmanial sphingolipid degradative enzyme (ISCL), another nSMase homologue (Zhang *et al.*, 2009; McConville and Naderer, 2011). ISCL IPCase activity is required for *L. major* promastigote stationary phase survival, most noticeably at acidic pH (Xu *et al.*, 2011). The enzyme's SMase function is necessary for amastigote proliferation and virulence in mammalian hosts (Zhang *et al.*, 2009, 2012). This means that the importance of leishmanial ISCL activity is linked to cell cycle stage (Zhang *et al.*, 2012). Similarly, inhibiting the nSMase/lyso-PC phospholipase C of *Plasmodium falciparum* disrupts parasite intra-erythrocytic proliferation, suggesting the protein could serve as a drug target (Hanada *et al.*, 2002). In previous research, TbnSMase was shown to catabolise SM effectively, but was inactive towards phosphatidylcholine (PC) (Young and Smith, 2010). This initial analysis has now been taken forward to provide a more comprehensive overview of TbnSMase lipid degradative activity and specificity.

Materials and Methods

Unless otherwise stated, all reagents and materials were purchased from Sigma, Promega, Thermo Scientific or VWR. Ceramide-1-phosphate (C-1-P) (d18:1/16:0), EPC (d17:1/12:0), SM (brain, porcine), dipalmitoyl-PC and dimyristoyl-PC (used as a mass spectrometry standard) were purchased from Avanti Polar Lipids. SM (d18:1/6:0), lyso-PC (from egg yolk), sphingosine-1-phosphate (S-1-P) (d18:1), and galactosylceramide were purchased from Sigma. EPC (from buttermilk, semi-synthetic) was purchased from Matreya LLC. Procyclic cell culture media were filter sterilised with either Millex GP 0.22 µm syringe filters or Triple Red 0.22 µm vacuum filtration units. Parasite cultures were maintained in Greiner Bio-One CELLSTAR® tissue culture flasks.

Recombinant expression of TbnSMase (Q57U95) in *Escherichia coli* (*E. coli*)

A pGEX-6P-1-TbnSMase expression construct was employed as previously described (Young and Smith, 2010). The expression construct was used to transform BL21/pLysSGold *E. coli*. Positive clones were selected using ampicillin-agar plates ($100 \mu\text{g mL}^{-1}$) supplemented with chloramphenicol ($34 \mu\text{g mL}^{-1}$). Three bacterial colonies were used to inoculate $3 \times 10 \text{ mL}$ of LB media (Miller composition, supplemented with $50 \mu\text{g mL}^{-1}$ ampicillin and $34 \mu\text{g mL}^{-1}$ chloramphenicol). After a 24 hour incubation, the 10 mL overnight cultures were combined in a single tube (30 mL total volume). The combined culture was then used to inoculate $3 \times 1 \text{ L}$ auto-induction (AI) media (Formedium, supplemented with $50 \mu\text{g mL}^{-1}$ ampicillin and $34 \mu\text{g mL}^{-1}$ chloramphenicol), using 10 mL of overnight culture per litre flask of AI media. Cells were grown at 37°C for 4 hours before the temperature was decreased to 25°C for a further 20 -hour incubation. Glutathione *S*-transferase (GST)-TbnSMase-enriched bacterial membranes were prepared from these cultures. Pellets of 500 mL spun-down culture were washed in PBS and stored at -80°C until they could be processed.

TbnSMase-enriched bacterial membrane preparation

The protocol described is adapted from methods previously outlined (Young and Smith, 2010). Pellets of 500 mL spun-down bacterial culture were suspended and lysed in 10 mL lysis buffer (50 mM Tris.HCl (pH 8.0), 300 mM NaCl, 10% glycerol (v/v), 5 mM MgCl_2 , 1 mM dithiothreitol (DTT)), containing 0.2 mg mL^{-1} lysozyme (Sigma), Merck Millipore Benzonase® Endonuclease ($250 \text{ units mL}^{-1}$ lysate) and 1 x protease inhibitor tablet (Roche, 11836170001). The lysis solution was incubated for 30 minutes at 37°C , followed by probe sonication at 4°C (6 minutes total, 30 seconds on/30 seconds off). The lysate was then centrifuged at $14,500 \times g$, 20 minutes. The product supernatant was divided amongst 3.2 mL capacity Beckman Coulter ultra-centrifuge tubes ($\times 3$) for ultra-centrifugation at $100,000 \times g$, 1 hour. Pellets were washed with 1.5 mL PBS. Each bacterial membrane pellet was then suspended in $500 \mu\text{L}$ buffer (100 mM Tris-HCl (pH 7.4), 10 mM MgCl_2 , 20% glycerol) using a combination of vortexing and water bath sonication (25°C , 4 minutes). The total membrane suspension ($1500 \mu\text{L}$ total volume) was mixed in a single tube and was then aliquoted ($50\text{--}100 \mu\text{L}$). Aliquots were flash-frozen using liquid nitrogen and stored at -80°C . Total protein in each membrane preparation was quantified using the Bichinonic acid (BCA) Protein Assay Kit (Thermo Scientific). The presence of TbnSMase in bacterial membranes was confirmed by mass spectrometry.

Amplex® UltraRed assay

Amplex® UltraRed assay coupling enzyme solutions were prepared from lyophilized powders using dH_2O , and were stored as small aliquots at -20°C . Alkaline phosphatase (AlkPhos) (Sigma) from bovine intestinal mucosa was prepared as a $400 \text{ units mL}^{-1}$ stock solution. Choline oxidase (ChoOx) (Sigma) from *Alcaligenes* sp. was prepared at 20 units mL^{-1} , horseradish peroxidase (HRP) (Sigma) at $200 \text{ units mL}^{-1}$. Desiccated aliquots of Amplex® UltraRed reagent (Thermo Scientific) were suspended in $340 \mu\text{L}$ DMSO, as directed by the manufacturer, and stored at -20°C in small aliquots. To assay the aqueous fractions of biphasically separated GST-TbnSMase SM substrate reactions, aqueous phases

were dried using a Savant SPD121P SpeedVac concentrator. The fractions were suspended in 100 μ L reaction buffer (100 mM HEPES Na (pH 7.4), 10 mM $MgCl_2$) and divided between 2 wells of a black 96-well reaction plate (50 μ L per well). Additional reaction buffer (50 μ L) was then added to each well. A mastermix of Amplex® assay components (coupling enzymes and Amplex® UltraRed reagent) was prepared. The mastermix accounted for the addition of 2 μ L AlkPhos, 1.5 μ L ChoOx, 1 μ L HRP, 0.25 μ L Amplex UltraRed reagent and 95.25 μ L reaction buffer per well (total reaction volume per well was 200 μ L). Change in fluorescence (Ex. 560 nm, Em. 587 nm) was then monitored for 1 hour using a Spectra Max Gemini XPS fluorescence plate reader at 37°C. Results were recorded using SoftMax Pro v 5.2 software.

Lipid substrate activity assays

Lipid substrates were suspended in 2% Triton X-100 to the desired stock concentration through vortexing and water-bath sonication (10 minutes). Substrate mass was substrate- and analysis-dependent (20-50 nmoles), but each was added to reactions (50-100 μ L total volume) to a final concentration of 0.1-0.2% Triton X-100. Substrates were incubated with TbnSMase-enriched bacterial membranes (~100 μ g total protein) in 1.5 mL solvent-resistant microcentrifuge tubes. In heat-inactivated protein reactions, protein aliquots were heated to 95°C (20 minutes) prior to substrate addition. Reactions were performed in 100 mM HEPES Na (pH 7.4), 10 mM $MgCl_2$ buffer. On substrate addition, reactions were mixed briefly and sonicated for 30 seconds in a water bath (25°C). Reaction tubes were then incubated at 37°C (4 hours) in a water bath. Following incubation, reactions were quenched with 800 μ L $CHCl_3$. If required, mass spectrometry standards (e.g. PC 28:0) were then added (500 pmoles), prior to the addition of 250 μ L dH_2O . The organic phase was isolated following the Bligh and Dyer biphasic separation method (Bligh and Dyer, 1959), and dried under nitrogen.

Parasite lysate N-[12-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino] dodecanoyl] (NBD)-IPC activity assays

The protocol described is adapted from methods previously outlined (Sutterwala *et al.*, 2008). Cells were suspended in lysis buffer (25 mM Tris (pH 7.5), 0.1% Triton X-100, 1 x protease inhibitor tablet (Roche, 11836170001) to a density of 2×10^8 cells mL^{-1} , and were incubated on ice for 5 minutes. Subsequently, 4×10^6 parasites from each stock were transferred to each reaction. Parasites were incubated with 0.8 nmoles NBD-IPC, in 50 mM Tris (pH 7.5), 5 mM $MgCl_2$, 5 mM DTT, 0.1 % Triton X-100 reaction buffer, for 1 hour at 25 °C with gentle agitation (protected from the light). Following incubation, reactions were quenched with the addition of 1 mL $CHCl_3$. Subsequently, 500 μ L MeOH and 200 μ L dH_2O were quickly added. Samples were vortex mixed, then left to stand (protected from the light). The organic phase from each sample was isolated through biphasic separation, and dried under nitrogen.

High-performance thin-layer chromatography

HPTLC analysis of EPC and NBD-IPC substrate reactions was conducted using a $CHCl_3$: MeOH: dH_2O solvent system (65:25:4). Dried lipid samples were resuspended in 2:1 $CHCl_3$: MeOH (10-20 μ L volume) and were gradually spotted onto HPTLC plates. EPC

reaction results were visualised by treating HPTLC plates with ninhydrin solution (1% w/v in butan-1-ol). NBD-IPC reaction results were visualised via fluorescence imaging using a Typhoon FLA 7000 (GE), with CY2 (filter Y520, 473 nm laser) and Sypro Ruby (filter O580, 473 nm laser) settings.

Procyclic form *T. brucei* lipid extract preparation

T. brucei (Lister 427 (29-13) strain) procyclic (PCF) parasites were grown in SDM-79 media at pH 7.4, as previously described (Brun and Schönenberger, 1979). Drugs G418 (15 µg mL⁻¹) and hygromycin (50 µg mL⁻¹) were included in the media in order to maintain the expression of a tetracycline repressor and T7 RNA polymerase (Wirtz *et al.*, 1999). A 10 ml culture of PCF cells (~1 x 10⁷ cells mL⁻¹) was pelleted via centrifugation at 800 x g, 10 minutes. The cell pellet was resuspended in a minimal volume of media (~500 µL) and transferred to a microcentrifuge tube for further centrifugation (3800 x g, 3 minutes). Cells were washed in 1 mL PBS, and then re-pelleted (3800 x g, 3 minutes). The pellet was resuspended in 200 µL PBS and transferred to a glass vial containing 750 µL 2:1 MeOH:CHCl₃ for biphasic separation, based on the method described by Bligh and Dyer (Bligh and Dyer, 1959). The sample was dried under nitrogen and stored at 4°C until use.

Electrospray tandem mass spectrometry

Lipid samples were analysed by electrospray tandem mass spectrometry (ESI-MS/MS) with an AB-Sciex Qtrap 4000 triple quadrupole mass spectrometer, incorporating an Advion TriVersa NanoMate nanoelectrospray ionisation source. Single-stage MS in negative ion mode was used to obtain survey scans of phosphatidylethanolamine (PE), ethanolamine-phosphoceramide (EPC), phosphatidylinositol (PI), inositol-phosphoceramide (IPC) and ceramide (Cer) species (cone voltage = 1.25 kV). Positive ion mode survey scans were used to detect phosphatidylcholine (PC) and sphingomyelin (SM) species (cone voltage = 1.25 kV). In tandem mass spectrometry, nitrogen was the collision gas. To examine PC/SM species, positive ion mode scans to detect precursors of m/z 184 were performed, with 50 eV collision energy (CE). In negative ion mode, precursors of m/z 196 scans allowed the identification of PE and EPC lipids, precursors of m/z 241 scans were used to observe PI and IPC species (CE = 60 eV). Spectra were acquired over or within the range of 120-1000 m/z, and each spectrum represents a minimum of 30 consecutive scans. Samples were run using a 1:1 solvent mixture of 2:1 MeOH: CHCl₃ and 6:7:2 acetonitrile: isopropanol: dH₂O.

Results

GST-TbnSMase was recombinantly expressed in *E. coli* to produce TbnSMase-enriched bacterial membranes, using previously described methods (Young and Smith, 2010). The presence of the GST-TbnSMase membrane protein was confirmed using mass spectrometry (Fig. S1). After isolating the bacterial membranes via ultra-centrifugation, it was possible to assay GST-TbnSMase activity directly from the membranes with minimal bacteria-derived background activity, removing the need for protein purification. This had also been achieved during previous research into TbnSMase activity (Young and Smith, 2010). To confirm the GST-TbnSMase recombinant protein was active, GST-TbnSMase-enriched bacterial membranes were first incubated at 37 °C for 4 hours with a sphingomyelin (SM) substrate.

The substrate used was Avanti Polar Lipids brain SM (product no. 860062). Although this product is enriched for SM 36:1 (d18:1/18:0), as a natural lipid preparation the product is a mixture of brain SM species. The spectra presented here are consistent with the recently released Avanti Polar Lipids fatty acid distribution analysis for this product (Fig. S2) (Avanti Polar Lipids, 2018). Following SM substrate incubation, reactions were biphasically separated using 2:1 CHCl₃: MeOH to isolate the lipid-rich organic phase. ESI-MS/MS was used to detect the levels of choline-containing (SM) lipid species in lipid samples derived from both active GST-TbnSMase and heat-inactivated GST-TbnSMase reactions (Fig. 2A and 2B, see also Fig. S3). A dimyristoyl-PC standard was added to each sample during lipid extraction, allowing SM substrate peak intensities to be normalised against the intensity of the internal standard. Relative peak intensities for each SM substrate species are shown (Fig. 2C).

The catabolic activity of GST-TbnSMase towards sphingomyelin had been demonstrated previously (Young and Smith, 2010), here providing confirmation that the GST-TbnSMase recombinant protein was active. However, the use of ESI-MS/MS allowed the relative turnover of individual SM species present in the substrate mixture to be compared (Fig. 2C). The results indicate that GST-TbnSMase is active towards SM species with a range of fatty acid chain lengths (C16-C24). There was a 2.6-fold (62%) decrease in SM 42:1 (d18:1/24:0)/SM 42:2 (d18:1/24:1), compared to a 1.5-fold (35%) decrease in SM 36:1 (d18:1/18:0), despite the latter lipid being the prevalent species in the SM substrate mixture. This may indicate GST-TbnSMase preferentially degrades sphingolipid species of specific fatty acid chain lengths. SM substrate catabolism was further confirmed by identification of product ceramide chloride adducts [M + Cl]⁻ in negative ion mode survey scans (Fig. 3). Product ceramides were observed in the active GST-TbnSMase reaction (Fig. 3A), and were absent from the heat-inactivated control (Fig. 3B). Additionally, aqueous fractions isolated during biphasic separation of SM substrate reactions were tested for the presence of choline phosphate. The aqueous fractions were used as substrates for the Amplex® UltraRed assay system. In this assay (Fig. S4), the coupling enzyme alkaline phosphatase (AlkPhos) is included to dephosphorylate choline phosphate, yielding choline. The choline produced then serves as a substrate for the second coupling enzyme in the system: choline oxidase (ChoOx). Only the aqueous fractions from the active GST-TbnSMase reactions, in the presence of alkaline phosphatase, induced significantly increased rates of fluorescence change (Fig. 3C). These results confirm GST-TbnSMase is a phosphodiesterase C enzyme, degrading SM substrates to form ceramide and choline phosphate.

Having established the GST-TbnSMase protein was active, the enzyme's activity towards a number of different sphingolipid substrates was examined. As already highlighted, *T. brucei* is known to produce SM, EPC and IPC. Thus, it was important to examine the activity of TbnSMase towards EPC and IPC sphingolipids. Firstly, GST-TbnSMase was incubated with an EPC substrate. The EPC substrate used was supplied by Mattreya LLC (product no. 1327), a semi-synthetic preparation derived from bovine buttermilk. No fatty acid distribution analysis is available for this product. However, the average molecular weight reported for the product (mw = 773) appears consistent with our analysis (Fig. 4A). Lipid extracts from the EPC substrate reactions were analysed in ESI-MS/MS negative ion mode survey scans. The EPC species present in the substrate (Fig. 4A) were efficiently degraded

by GST-TbnSMase, yielding ceramide products (Fig. 4B). These products were absent from the heat-inactivated GST-TbnSMase control and the EPC/Triton X-100 detergent mixed micelles supplied to the reactions (Fig. 4C and 4D). Additionally, GST-TbnSMase degradative activity towards EPC was shown via HPTLC (Fig. S5). GST-TbnSMase was also incubated with a lipid substrate mixture containing equimolar concentrations of SM (d18:1/6:0, Avanti Polar Lipids product no.860582) and EPC (d17:1/12:0, Avanti Polar Lipids product no.860529). This competition assay indicated GST-TbnSMase lacks a sphingolipid substrate preference (Fig. S6). However, given the high levels of substrate turnover for both species, it is possible increasing the concentrations of both substrates may lead to a more marked preference for SM over EPC. Additionally, as EPC (d17:1/12:0) is the only pure EPC substrate commercially available, it is not possible to assess the impact of varying the sphingoid base and fatty acid composition on substrate turnover.

Currently, pure IPC lipid species are only available commercially through custom synthesis. GST-TbnSMase was shown to catabolise a custom synthesised NBD-conjugated IPC substrate (kindly gifted by Dr K. Zhang) (Fig. S7). However, the synthetic nature of this IPC substrate makes it difficult to draw conclusions regarding the physiological relevance of this activity. It is well established that the prevalent sphingolipid in procyclic form *T. brucei* is IPC (Richmond *et al.*, 2010). Therefore, a lipid extract from procyclic parasites was used to form a mixed micelle IPC substrate for GST-TbnSMase. Negative ion mode scans to detect inositol-containing lipids (precursors of m/z 241) were used to identify the IPC species present in the procyclic *T. brucei* extract (Fig. 5A). Negative ion mode survey scans were then employed to search for ceramide chloride adducts $[M + Cl]^-$. Significant peaks corresponding to ceramide species were observed in the active GST-TbnSMase reaction (Fig. 5B), and were only observed at low levels in the heat-inactivated control (Fig. 5C, see also Fig. S8). Taken together, these results suggest GST-TbnSMase is also capable of catabolising natural IPC species to form ceramide and inositol-1-phosphate.

The ability of GST-TbnSMase to degrade SM, EPC and IPC indicates the enzyme does not distinguish between its sphingolipid substrates based upon headgroup identity. To further explore this finding, GST-TbnSMase was incubated with a ceramide-1-phosphate (d18:1/16:0) substrate (Avanti Polar Lipids product no. 860533). A ceramide (d18:1/16:0) chloride adduct $[M + Cl]^-$ was apparent in the lipid extract from the active GST-TbnSMase reaction (Fig. 6A), and was absent from the control (Fig. 6B). This result suggests lipid headgroups are not involved in GST-TbnSMase substrate recognition. However, GST-TbnSMase does not appear to degrade glycosphingolipids, as no apparent catabolism was observed upon incubating GST-TbnSMase with a mixture of galactosylceramide substrate species (Sigma product no. C4905) (Fig. S9). This indicates that although GST-TbnSMase does not require a headgroup for lipid substrate turnover, features of the headgroup can impede substrate catabolism. It was also observed that the enzyme cannot degrade S-1-P (d18:1, Avanti Polar Lipids product no. 860492), as the level of the substrate species remained unchanged in lipid extracts from an active GST-TbnSMase reaction and controls (data not shown). This finding indicates ceramide is a crucial component of GST-TbnSMase sphingolipid substrates.

Finally, GST-TbnSMase activity towards choline-containing phospholipids was reassessed. During previous research into TbnSMase, catabolic activity towards PC and *lyso*-PC lipid substrates could not be detected (Young and Smith, 2010). Re-assessing GST-TbnSMase activity towards PC (16:0/16:0) using ESI-MS/MS analysis failed to establish any substrate turnover (Avanti Polar Lipids product no. 850355) (data not shown). However, precursors of *m/z* 184 scans in positive ion mode revealed that GST-TbnSMase does turnover *lyso*-PC species (Fig. 7). There was a marked reduction in *lyso*-PCs (16:0) and (18:0) only in the presence of active GST-TbnSMase (Fig. 7A), relative to a PC (10:0/10:0) standard included in all *lyso*-PC reactions. This decrease did not occur in the control (Fig. 7B). Additionally, the *lyso*-PC analogues miltefosine and edelfosine were previously shown to inhibit GST-TbnSMase (Young and Smith, 2010). This led to speculation that the previously observed inhibition of the enzyme's activity by *lyso*-PC analogues may be due to these compounds acting as competing substrates. Testing miltefosine as a potential substrate for GST-TbnSMase (5-50 nmoles) in the Amplex® UltraRed assay system did not produce any data to suggest this *lyso*-PC analogue is turned over by GST-TbnSMase (data not shown). This indicates *lyso*-PC analogues are not competitive substrates for GST-TbnSMase. However, the possibility remains that these compounds may be tightly bound to the enzyme's active site, preventing the ChoP release required for assay detection.

Discussion

Sphingolipid metabolism in kinetoplastid parasites has long been established as a potential target for anti-parasitic drug development (Smith and Bütikofer, 2010; Mina and Denny, 2017). However, research has focused almost exclusively on the pathways involved in sphingolipid biosynthesis. Initial research into the nSMase found in *T. brucei* showed this enzyme has sphingolipid catabolic activity (Young and Smith, 2010). TbnSMase is the only currently identified *T. brucei* protein that displays this function. Unusually, the parasites appear to lack phospholipase D activity, which generally facilitates eukaryotic SM and PC catabolism. The substrate specificity of TbnSMase was examined to improve understanding of *T. brucei* sphingolipid catabolism and salvage.

TbnSMase is now known to turnover SM, EPC and IPC sphingolipid species. This is consistent with the established sphingolipid composition of *T. brucei* (Richmond *et al.*, 2010; Guan and Mäser, 2017): IPC predominates in procyclic parasites, whilst almost equal proportions of SM and EPC species are found in the bloodstream form (Guan and Mäser, 2017). In light of this knowledge, it may seem unsurprising that TbnSMase is active towards all three of these sphingolipid classes, only distinguished structurally by their headgroup (choline, ethanolamine and inositol). However, to our knowledge, this breadth of sphingolipid substrate specificity has not been documented previously for a lipid catabolic enzyme. It is possible that other sphingolipid degradative enzymes (especially those found in other kinetoplastids) share this ability but have not been tested. If this wide-ranging substrate specificity is not found in mammalian nSMase homologues, it may be possible to exploit these differences to create TbnSMase-specific substrate analogue inhibitors. The TbnSMase activity reported here precludes the need for other sphingolipid degradative enzymes in the ER and rationalises the constitutive expression of this enzyme in both procyclic and bloodstream forms. However, no activity towards glycosphingolipids was observed,

indicating phosphate groups may be an obligatory feature of TbnSMase substrates. It has been reported that *T. brucei* possess trace levels of glycosphingolipids, glucosylceramide species having been identified in several studies (Uemura *et al.*, 2006; Fridberg *et al.*, 2008; Richmond *et al.*, 2010). These could be endocytosed host glycosphingolipids, as no glycosphingolipid biosynthetic enzymes have been formally identified in *T. brucei* (Uemura *et al.*, 2006; Richmond *et al.*, 2010; Guan and Mäser, 2017). Only galactosylceramide species were tested as possible substrates for TbnSMase, thus it remains possible the enzyme is active towards other glycosphingolipids. Alternatively, another (other) unidentified enzyme(s) may be responsible for *T. brucei* glycosphingolipid catabolism, possibly within the lysosome.

ESI-MS/MS analysis indicates that TbnSMase preferentially catabolises SM species with specific fatty acid chain lengths. A more significant decrease in SM 42:1 (d18:1/24:0)/SM 42:2 (d18:1/24:1) occurred relative to SM 36:1 (d18:1/18:0), despite the latter species being more prevalent in the substrate mixture. This suggests that TbnSMase activity may be geared towards recycling specific long-chain fatty acids, which can then be utilised in other biosynthetic processes. Defining a crystal structure for TbnSMase may reinforce these preliminary observations, particularly if the structure provides insight into substrate binding and potential regulation. Few crystal structures for nSMase proteins are currently available, and most studies have focused on the binding of choline phosphate to the active site (Openshaw *et al.*, 2005; Ago *et al.*, 2006). However, TbnSMase does not seem to distinguish between its substrates based on headgroup identity, instead appearing to preferentially degrade substrates with specific fatty acids. This finding indicates that the fatty acid composition of lipid substrates may be of greater interest when considering enzyme-substrate interactions. In support of this view, TbnSMase was shown to actively degrade ceramide-1-phosphate, which lacks a polar alcohol headgroup entirely. However, the enzyme was unable to catabolise sphingosine-1-phosphate, indicating the presence of an amide bound fatty acid at the *sn*-2 position is vital for sphingolipid substrate recognition. Indeed, in the case of TbnSMase, the critical aspect of lipid substrate recognition appears to centre on the binding of the phosphate and fatty acid moieties to sphingosine or glycerol backbones. TbnSMase is now known to degrade *lyso*-PC in addition to sphingolipids. This aspect of TbnSMase activity brings the enzyme in line with the nSMase found in *Plasmodium falciparum* parasites (PfnSMase) (Hanada *et al.*, 2002). Both PfnSMase and TbnSMase are inactive towards PC substrates, despite their ability to degrade *lyso*-PCs. This points to the diacylglycerol moiety of phospholipids impairing substrate binding to these SMase enzymes, and that removal of the fatty acid at the *sn*-2 position alleviates this inhibition. Thus, the requirements for glycerophospholipid recognition are the inverse of sphingophospholipid recognition.

TbnSMase is the first identified *T. brucei* enzyme shown to be capable of degrading *lyso*-PCs, which are believed to be a primary source of parasite choline during bloodstream infection (Bowes *et al.*, 1993; Smith and Bütikofer, 2010; Macêdo *et al.*, 2013). This is due to the parasites lacking a choline *de novo* biosynthesis pathway (Smith and Bütikofer, 2010), and *lyso*-PC concentration in the blood being 10-fold greater than choline (Macêdo *et al.*, 2013). Mammalian bloodstream *T. brucei* require an abundant source of choline, as over 50% of their lipid complement consists of choline-containing lipids (Smith and Bütikofer,

2010). The *T. brucei* phospholipase A1 was shown to degrade PC, but not *lyso*-PC species (Richmond and Smith, 2007a; b). A plasma membrane phospholipase that degrades *lyso*-PC has been postulated (Bowes *et al.*, 1993) but has yet to be identified. This activity in TbnSMase indicates the enzyme may be responsible for *lyso*-PC turnover in the ER. Research into the essentiality of TbnSMase showed that compromised enzyme function led to a concomitant decrease in the parasite's rate of endocytosis (Young and Smith, 2010). This could have wide-ranging effects on the parasites, but was thought to have particularly impacted *T. brucei* choline homeostasis due to the parasites' dependence upon endocytosed and recycled choline-containing lipids. This impact was indicated by a marked decrease in phosphatidylcholine (PC) and increased intracellular diacylglycerol (DAG), suggesting PC *de novo* biosynthesis via the Kennedy pathway had been disrupted (Young and Smith, 2010). The newly discovered ability of TbnSMase to degrade *lyso*-PC and SM species aligns with these observations, indicating decreased enzyme activity has a direct impact on choline homeostasis. This underlines the importance of TbnSMase function in sustaining the intracellular choline metabolite levels required for parasite survival and propagation.

Given TbnSMase is able to degrade various sphingolipids and *lyso*-PC, it seems likely that the enzyme will also be able to catabolise other *lyso*-phospholipids, particularly those with either an ethanolamine-phosphate or inositol-phosphate head group. The promiscuous activity of TbnSMase, likely explains the rather unusual fact that *T. brucei* parasites have not retained a phospholipase D enzyme, which facilitates these degradative processes in other eukaryotes.

Further research is required to identify and characterise other enzymes that underpin lipid catabolism and salvage in these kinetoplastid parasites, which represent a valuable model system for eukaryotic lipid metabolism (Serricchio and Bütikofer, 2011). As in the case of TbnSMase, the activity of these enzymes may prove vital, opening new areas of *T. brucei* biochemistry to drug development.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

NBD-IPC was kindly gifted by Dr. K. Zhang (Texas Tech University). The Biomedical Sciences Research Complex Mass Spectrometry and Proteomics Facility, University of St Andrews, performed mass-spectrometric analysis to identify GST-TbnSMase protein.

Financial Support

This work was supported primarily through the European Community's Seventh Framework Programme under grant agreements No. 602773 (Project KINDRED), with additional support from Wellcome Trust Project grant (086658); Medical Research Council (MR/Mo20118/1) and the School of Chemistry (The University of St Andrews).

References

- Ago H, Oda M, Takahashi M, Tsuge H, Ochi S, Katunuma N, Miyano M, Sakurai J. Structural basis of the sphingomyelin phosphodiesterase activity in neutral sphingomyelinase from *Bacillus cereus*.

- Journal of Biological Chemistry. 2006; 281:16157–67. DOI: 10.1074/jbc.M601089200 [PubMed: 16595670]
- Avanti Polar Lipids. [accessed 24 January 2018] 860062 Brain SM, Sphingomyelin (Brain, Porcine). 2018. Retrieved from Avanti Polar Lipids website: <https://avantilipids.com/product/860062>
- Bligh EG, Dyer WJ. A Rapid Method of total Lipid Extraction and Purification. Canadian Journal of Biochemistry and Physiology. 1959; 37:911–917. DOI: 10.1139/o59-099
- Bowes E, Samad H, Jiang P, Weaver B, Mellors A. The acquisition of lysophosphatidylcholine by African trypanosomes. Journal of Biological Chemistry. 1993; 268:13885–92. [PubMed: 8314756]
- Brun R, Schönenberger M. Cultivation and in vitro cloning or procyclic culture forms of *Trypanosoma brucei* in a semi-defined medium. Short communication. Acta Tropica. 1979; 36:289–292. DOI: 10.5169/seals-312533 [PubMed: 43092]
- De Lederkremer RM, Agusti R, Docampo R. Inositolphosphoceramide metabolism in *Trypanosoma cruzi* as compared with other trypanosomatids. Journal of Eukaryotic Microbiology. 2011; 58:79–87. DOI: 10.1111/j.1550-7408.2011.00533.x [PubMed: 21332877]
- Denny PW, Goulding D, Ferguson MAJ, Smith DF. Sphingolipid-free *Leishmania* are defective in membrane trafficking, differentiation and infectivity. Molecular Microbiology. 2004; 52:313–27. DOI: 10.1111/j.1365-2958.2003.03975.x [PubMed: 15066023]
- Denny PW, Shams-Eldin H, Price HP, Smith DF, Schwartz RT. The protozoan inositol phosphorylceramide synthase: a novel drug target which defines a new class of sphingolipid synthase. Journal of Biological Chemistry. 2006; 281:28200–28209. DOI: 10.1074/jbc.M600796200 [PubMed: 16861742]
- Fridberg A, Olson CL, Nakayasu ES, Tyler KM, Almeida IC, Engman DM. Sphingolipid synthesis is necessary for kinetoplast segregation and cytokinesis in *Trypanosoma brucei*. Journal of Cell Science. 2008; 121:522–35. DOI: 10.1242/jcs.016741 [PubMed: 18230649]
- Gerold P, Schwarz RT. Biosynthesis of glycosphingolipids de-novo by the human malaria parasite *Plasmodium falciparum*. Molecular and Biochemical Parasitology. 2001; 112:29–37. DOI: 10.1016/S0166-6851(00)00336-4 [PubMed: 11166384]
- Goren MA, Fox BG, Bangs JD. Amino acid determinants of substrate selectivity in the *Trypanosoma brucei* sphingolipid synthase family. Biochemistry. 2011; 50:8853–8861. DOI: 10.1021/bi200981a [PubMed: 21899277]
- Guan XL, Mäser P. Comparative sphingolipidomics of disease-causing trypanosomatids reveal unique lifecycle- and taxonomy-specific lipid chemistries. Scientific Reports. 2017; 7:1–13. DOI: 10.1038/s41598-017-13931-x [PubMed: 28127051]
- Hanada K, Palacpac NMQ, Magistrado PA, Kurokawa K, Rai G, Sakata D, Hara T, Horii T, Nishijima M, Mitamura T. *Plasmodium falciparum* phospholipase C hydrolyzing sphingomyelin and lysocholinephospholipids is a possible target for malaria chemotherapy. Journal of Experimental Medicine. 2002; 195:23–34. [PubMed: 11781362]
- Jenkins RW, Canals D, Hannun YA. Roles and regulation of secretory and lysosomal acid sphingomyelinase. Cellular Signalling. 2009; 21:836–846. DOI: 10.1016/j.cellsig.2009.01.026 [PubMed: 19385042]
- Jenkins RW, Idkowiak-Baldys J, Simbari F, Canals D, Roddy P, Riner CD, Clarke CJ, Hannun YA. A novel mechanism of lysosomal acid sphingomyelinase maturation: requirement for carboxyl-terminal proteolytic processing. Journal of Biological Chemistry. 2011; 286:3777–88. DOI: 10.1074/jbc.M110.155234 [PubMed: 21098024]
- Kolter T, Sandhoff K. Sphingolipids-Their Metabolic Pathways and the Pathobiochemistry of Neurodegenerative Diseases. Angewandte Chemie (International ed. in English). 1999; 38:1532–1568. DOI: 10.1002/(SICI)1521-3773(19990601)38:11<1532::AID-ANIE1532>3.0.CO;2-U [PubMed: 29710982]
- Macêdo JP, Schmidt RS, Mäser P, Rentsch D, Vial HJ, Sigel E, Bütikofer P. Characterization of choline uptake in *Trypanosoma brucei* procyclic and bloodstream forms. Molecular and Biochemical Parasitology. 2013; 190:16–22. DOI: 10.1016/j.molbiopara.2013.05.007 [PubMed: 23747277]
- McConville MJ, Naderer T. Metabolic pathways required for the intracellular survival of *Leishmania*. Annual Review of Microbiology. 2011; 65:543–61. DOI: 10.1146/annurev-micro-090110-102913

- Mina JGM, Denny PW. Everybody needs sphingolipids, right! Mining for new drug targets in protozoan sphingolipid biosynthesis. *Parasitology*. 2017; :1–14. DOI: 10.1017/S0031182017001081
- Mina JG, Pan S-Y, Wansadhipathi NK, Bruce CR, Shams-Eldin H, Schwarz RT, Steel PG, Denny PW. The *Trypanosoma brucei* sphingolipid synthase, an essential enzyme and drug target. *Molecular and Biochemical Parasitology*. 2009; 168:16–23. DOI: 10.1016/j.molbiopara.2009.06.002 [PubMed: 19545591]
- Mugnier MR, Stebbins CE, Papavasiliou FN. Masters of Disguise: Antigenic Variation and the VSG Coat in *Trypanosoma brucei*. *PLoS Pathogens*. 2016; 12:1–6. DOI: 10.1371/journal.ppat.1005784
- Openshaw AEA, Race PR, Monzó HJ, Vázquez-Boland J-A, Banfield MJ. Crystal structure of SmcL, a bacterial neutral sphingomyelinase C from *Listeria*. *Journal of Biological Chemistry*. 2005; 280:35011–7. DOI: 10.1074/jbc.M506800200 [PubMed: 16093240]
- Richmond GS, Smith TK. A novel phospholipase from *Trypanosoma brucei*. *Molecular Microbiology*. 2007a; 63:1078–1095. DOI: 10.1111/j.1365-2958.2006.05582.x.A [PubMed: 17238918]
- Richmond GS, Smith TK. The role and characterization of phospholipase A1 in mediating lysophosphatidylcholine synthesis in *Trypanosoma brucei*. *Biochemical Journal*. 2007b; 405:319–29. DOI: 10.1042/BJ20070193 [PubMed: 17402937]
- Richmond GS, Gibellini F, Young SA, Major L, Denton H, Lilley A, Smith TK. Lipidomic analysis of bloodstream and procyclic form *Trypanosoma brucei*. *Parasitology*. 2010; 137:1357–92. DOI: 10.1017/S0031182010000715 [PubMed: 20602846]
- Serricchio M, Bütikofer P. *Trypanosoma brucei*: a model micro-organism to study eukaryotic phospholipid biosynthesis. *FEBS journal*. 2011; 278:1035–46. DOI: 10.1111/j.1742-4658.2011.08012.x [PubMed: 21232016]
- Sevova ES, Goren MA, Schwartz KJ, Hsu F-F, Turk J, Fox BG, Bangs JD. Cell-free synthesis and functional characterization of sphingolipid synthases from parasitic trypanosomatid protozoa. *Journal of Biological Chemistry*. 2010; 285:20580–7. DOI: 10.1074/jbc.M110.127662 [PubMed: 20457606]
- Shaw APM, Cecchi G, Wint GRW, Mattioli RC, Robinson TP. Mapping the economic benefits to livestock keepers from intervening against bovine trypanosomosis in Eastern Africa. *Preventive Veterinary Medicine*. 2014; 113:197–210. DOI: 10.1016/j.prevetmed.2013.10.024 [PubMed: 24275205]
- Smith TK, Bütikofer P. Lipid metabolism in *Trypanosoma brucei*. *Molecular and Biochemical Parasitology*. 2010; 172:66–79. DOI: 10.1016/j.molbiopara.2010.04.001 [PubMed: 20382188]
- Sutterwala SS, Hsu F-F, Sevova ES, Schwartz KJ, Zhang K, Key P, Turk J, Beverley SM, Bangs JD. Developmentally regulated sphingolipid synthesis in African trypanosomes. *Molecular Microbiology*. 2008; 70:281–96. DOI: 10.1111/j.1365-2958.2008.06393.x [PubMed: 18699867]
- Tidhar R, Futerman AH. The complexity of sphingolipid biosynthesis in the endoplasmic reticulum. *Biochimica et Biophysica Acta*. 2013; 1833:2511–8. DOI: 10.1016/j.bbamcr.2013.04.010 [PubMed: 23611790]
- Uemura A, Watarai S, Kushi Y, Kasama T, Ohnishi Y, Kodama H. Analysis of neutral glycosphingolipids from *Trypanosoma brucei*. *Veterinary Parasitology*. 2006; 140:264–272. DOI: 10.1016/j.vetpar.2006.04.028 [PubMed: 16806714]
- Wirtz E, Leal S, Ochatt C, Cross GA. A tightly regulated inducible expression system for conditional gene knock-outs and dominant-negative genetics in *Trypanosoma brucei*. *Molecular and Biochemical Parasitology*. 1999; 99:89–101. [PubMed: 10215027]
- World Health Organization. [accessed 25 August 2017] Trypanosomiasis, human African (sleeping sickness). 2017a. Retrieved from the World Health Organization website: <http://www.who.int/mediacentre/factsheets/fs259/en/>
- World Health Organization. Integrating neglected tropical diseases into global health and development: fourth WHO report on neglected tropical diseases. Geneva, Switzerland: World Health Organization; 2017b.
- Xu W, Xin L, Soong L, Zhang K. Sphingolipid degradation by *Leishmania major* is required for its resistance to acidic pH in the mammalian host. *Infection and Immunity*. 2011; 79:3377–87. DOI: 10.1128/IAI.00037-11 [PubMed: 21576322]

- Young SA, Smith TK. The essential neutral sphingomyelinase is involved in the trafficking of the variant surface glycoprotein in the bloodstream form of *Trypanosoma brucei*. *Molecular Microbiology*. 2010; 76:1461–82. DOI: 10.1111/j.1365-2958.2010.07151.x [PubMed: 20398210]
- Zhang K, Pompey JM, Hsu F-F, Key P, Bandhuvula P, Saba JD, Turk J, Beverley SM. Redirection of sphingolipid metabolism toward de novo synthesis of ethanolamine in *Leishmania*. *EMBO journal*. 2007; 26:1094–104. DOI: 10.1038/sj.emboj.7601565 [PubMed: 17290222]
- Zhang O, Wilson MC, Xu W, Hsu F-F, Turk J, Kuhlmann FM, Wang Y, Soong L, Key P, Beverley SM, Zhang K. Degradation of host sphingomyelin is essential for *Leishmania* virulence. *PLoS pathogens*. 2009; 5:e1000692.doi: 10.1371/journal.ppat.1000692 [PubMed: 20011126]
- Zhang O, Xu W, Balakrishna Pillai A, Zhang K. Developmentally regulated sphingolipid degradation in *Leishmania major*. *PloS one*. 2012; 7:e31059.doi: 10.1371/journal.pone.0031059 [PubMed: 22299050]

A

B

Fig. 1. *Trypanosoma brucei* sphingolipid metabolism.

A) The currently proposed pathway for *T. brucei de novo* sphingolipid biosynthesis is shown. SPT-serine-palmitoyltransferase (Q580D0); 3-KSR – 3-ketosphinganine reductase (Q38BJ6); CerS – ceramide synthase (Q57V92, Q583F9); DES – dihydroceramide desaturase (Q583N4); TbSLs 1-4 – *T. brucei* sphingolipid synthases 1-4 (Q38E53; Q38E54; Q38E55; Q38E56). Biosynthesis of ceramide (36:1) has been used here as an example. B) A simplified overview of eukaryotic sphingolipid degradation is provided (omitting glycosphingolipid catabolic pathways). A representative sphingolipid species

(sphingomyelin (36:1)) is degraded in a step-wise process involving sphingomyelinases (SMases) and ceramidases (CDases). Lipid headgroups, such as choline phosphate, and sphingosine can be recycled to participate in *de novo* biosynthesis via the salvage pathway (dashed arrows). Products ceramide and sphingosine can also be phosphorylated to produce signalling molecules ceramide-1-phosphate and sphingosine-1-phosphate respectively. ATP – adenosine triphosphate; ADP – adenosine diphosphate; CERK – ceramide kinase; SphK – sphingosine kinase.

Fig. 2. ESI-MS/MS analysis of sphingomyelin substrate reactions.

Spectra are ESI-MS/MS precursor ion scans to detect choline-containing lipids (precursors of m/z 184) in positive ion mode. (A) GST-TbnSMase-enriched bacterial membranes plus SM substrate. (B) heat-inactivated (HI) GST-TbnSMase enriched bacterial membranes plus SM substrate. (†) Highlights the dimyristoyl-PC (28:0) standard (500 pmoles). (C) Peak intensities (cps), normalised against the intensity of the dimyristoyl-PC (28:0) standard, for each significant sphingomyelin (SM) substrate lipid species are depicted. Values are mean

intensities for triplicate reactions ($n = 3$). Error bars represent the standard error of each mean ($\pm$).

Fig. 3. GST-TbnSMase catabolism of sphingomyelin yields ceramide and choline phosphate. Spectra are ESI-MS/MS survey scans in negative ion mode. A) GST-TbnSMase-enriched bacterial membranes plus SM substrate. B) heat-inactivated (HI) TbnSMase-enriched bacterial membranes plus SM substrate. Annotated ceramides have formed chloride adducts $[M + Cl]^-$. (*) Highlights previously identified significant contaminants of negative ion mode surveys thought to be associated with the detergent. C) Aqueous fractions of sphingomyelin substrate reactions were used as substrates for the Amplex® UltraRed assay system, plus (+) or minus (-) the coupling-enzyme alkaline phosphatase (AlkPhos). Change in fluorescence

(millirelative-fluorescence units per minute (mrfu min⁻¹)) was monitored spectrophotometrically. Values represent average rate of fluorescence change for aqueous fractions derived from triplicate reactions (n = 3). Error bars represent the standard error of each mean ($\pm$).

Fig. 4. ESI-MS/MS analysis of ethanolamine-phosphoceramide substrate reactions. Spectra are ESI-MS/MS survey scans in negative ion mode. A) EPC only (minus Triton X-100 detergent). B) GST-TbnSMase-enriched bacterial membranes plus EPC substrate. Annotated ceramides have formed chloride adducts $[M + Cl]^-$. C) heat-inactivated GST-TbnSMase-enriched bacterial membranes plus EPC substrate. D) EPC/ Triton X-100 detergent mixed micelle substrate only. E) Non-TbnSMase-expressing bacterial membranes plus EPC substrate. (*) Highlights previously identified significant contaminants of negative ion mode surveys thought to be associated with the detergent.

Fig. 5. ESI-MS/MS analysis of *T. brucei* procyclic-extract (inositol-phosphoceramide) substrate reactions.

A) ESI-MS/MS precursor ion scan of the procyclic lipid extract (IPC substrate) to detect inositol-containing lipids (precursors of m/z 241), in negative ion mode. The extract contains dihydroxylated ceramides, as well as trihydroxylated ceramides, the later denoted as 't-'. B) ESI-MS/MS negative ion mode survey scans were used to detect ceramides in GST-TbnSMase plus IPC substrate; C) heat-inactivated GST-TbnSMase-enriched bacterial membranes plus IPC substrate; D) IPC/ Triton X-100 detergent mixed micelle substrate only

and E) Non-TbnSMase-expressing bacterial membranes plus IPC substrate reactions. Annotated ceramides have formed chloride adducts $[M + Cl]^-$.

Fig. 6. GST-TbnSMase catabolism of ceramide-1-phosphate yields ceramide. Spectra are ESI-MS/MS survey scans in negative ion mode. A) GST-TbnSMase-enriched bacterial membranes plus ceramide-1-phosphate (C-1-P) substrate. B) Non-TbnSMase-expressing bacterial membranes plus ceramide-1-phosphate substrate. The annotated ceramide (Cer) product species has formed a chloride adduct $[M + Cl]^-$.

Fig. 7. ESI-MS/MS analysis of *lyso*-PC substrate reactions.

Spectra are ESI-MS/MS precursor ion scans to detect choline-containing lipids (precursors of m/z 184) in positive ion mode. A) GST-TbnSMase-enriched bacterial membranes with *lyso*-PC substrate. B) non-TbnSMase-expressing bacterial membranes with *lyso*-PC substrate. (†) Highlights the didecanoyl-PC (20:0) standard (500 pmoles). (*) Highlights previously identified significant contaminants of positive ion mode scans thought to be associated with the detergent.